Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management.

Xicota L, Rodríguez J, Langohr K, Fitó M, Dierssen M, de la Torre R; TESDAD study group.

Clin Nutr. 2019 Jun 8. pii: S0261-5614(19)30255-9. doi: 10.1016/j.clnu.2019.05.028. [Epub ahead of print]

PMID:
31229326
2.

Pergola-web: a web server for the visualization and analysis of longitudinal behavioral data using repurposed genomics tools and standards.

Espinosa-Carrasco J, Pulido TH, Erb I, Dierssen M, Ponomarenko J, Notredame C.

Nucleic Acids Res. 2019 Jul 2;47(W1):W600-W604. doi: 10.1093/nar/gkz414.

3.

A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.

de la Torre R, de Sola S, Farré M, Xicota L, Cuenca-Royo A, Rodriguez J, León A, Langohr K, Gomis-González M, Hernandez G, Esteba S, Del Hoyo L, Sánchez-Gutiérrez J, Cortés MJ, Ozaita A, Espadaler JM, Novell R, Martínez-Leal R, Milá M, Dierssen M; TESXF Study Group.

Clin Nutr. 2019 Mar 25. pii: S0261-5614(19)30082-2. doi: 10.1016/j.clnu.2019.02.028. [Epub ahead of print]

PMID:
30962103
4.

Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society.

Reeves RH, Delabar J, Potier MC, Bhattacharyya A, Head E, Lemere C, Dekker AD, De Deyn P, Caviedes P, Dierssen M, Busciglio J.

Mol Syndromol. 2019 Jan;9(6):279-286. doi: 10.1159/000494231. Epub 2018 Oct 30.

5.

Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome.

Navarro-Romero A, Vázquez-Oliver A, Gomis-González M, Garzón-Montesinos C, Falcón-Moya R, Pastor A, Martín-García E, Pizarro N, Busquets-Garcia A, Revest JM, Piazza PV, Bosch F, Dierssen M, de la Torre R, Rodríguez-Moreno A, Maldonado R, Ozaita A.

Neurobiol Dis. 2019 May;125:92-106. doi: 10.1016/j.nbd.2019.01.014. Epub 2019 Jan 25.

PMID:
30685352
6.

Overweight Mice Show Coordinated Homeostatic and Hedonic Transcriptional Response across Brain.

De Toma I, Grabowicz IE, Fructuoso M, Trujillano D, Wilczyński B, Dierssen M.

eNeuro. 2018 Jan 8;5(6). pii: ENEURO.0287-18.2018. doi: 10.1523/ENEURO.0287-18.2018. eCollection 2018 Nov-Dec.

7.

Metabolomics predicts the pharmacological profile of new psychoactive substances.

Olesti E, De Toma I, Ramaekers JG, Brunt TM, Carbó ML, Fernández-Avilés C, Robledo P, Farré M, Dierssen M, Pozo ÓJ, de la Torre R.

J Psychopharmacol. 2019 Mar;33(3):347-354. doi: 10.1177/0269881118812103. Epub 2018 Nov 19.

PMID:
30451567
8.

Pergola: Boosting Visualization and Analysis of Longitudinal Data by Unlocking Genomic Analysis Tools.

Espinosa-Carrasco J, Erb I, Hermoso Pulido T, Ponomarenko J, Dierssen M, Notredame C.

iScience. 2018 Nov 30;9:244-257. doi: 10.1016/j.isci.2018.10.023. Epub 2018 Oct 26.

9.

Translating molecular advances in Down syndrome and Fragile X syndrome into therapies.

Faundez V, De Toma I, Bardoni B, Bartesaghi R, Nizetic D, de la Torre R, Cohen Kadosh R, Herault Y, Dierssen M, Potier MC; Down Syndrome and Other Genetic Developmental Disorders ECNP Network.

Eur Neuropsychopharmacol. 2018 Jun;28(6):675-690. doi: 10.1016/j.euroneuro.2018.03.006. Epub 2018 Jun 7. Review.

PMID:
29887288
10.

Corrigendum to "Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome" [Free Radic. Biol. Med. 114 (2018) 122-130].

Fructuoso M, Rachdi L, Philippe E, Denis RG, Magnan C, Le Stunff H, Janel N, Dierssen M.

Free Radic Biol Med. 2018 Apr;118:150. doi: 10.1016/j.freeradbiomed.2018.02.029. Epub 2018 Mar 7. No abstract available.

PMID:
29525132
11.

Mutations in L-type amino acid transporter-2 support SLC7A8 as a novel gene involved in age-related hearing loss.

Espino Guarch M, Font-Llitjós M, Murillo-Cuesta S, Errasti-Murugarren E, Celaya AM, Girotto G, Vuckovic D, Mezzavilla M, Vilches C, Bodoy S, Sahún I, González L, Prat E, Zorzano A, Dierssen M, Varela-Nieto I, Gasparini P, Palacín M, Nunes V.

Elife. 2018 Jan 22;7. pii: e31511. doi: 10.7554/eLife.31511.

12.

Time-course and dynamics of obesity-related behavioral changes induced by energy-dense foods in mice.

Espinosa-Carrasco J, Burokas A, Fructuoso M, Erb I, Martín-García E, Gutiérrez-Martos M, Notredame C, Maldonado R, Dierssen M.

Addict Biol. 2018 Mar;23(2):531-543. doi: 10.1111/adb.12595. Epub 2018 Jan 10.

PMID:
29318700
13.

Extinction and reinstatement of an operant responding maintained by food in different models of obesity.

Burokas A, Martín-García E, Espinosa-Carrasco J, Erb I, McDonald J, Notredame C, Dierssen M, Maldonado R.

Addict Biol. 2018 Mar;23(2):544-555. doi: 10.1111/adb.12597. Epub 2017 Dec 28.

PMID:
29282813
14.

Loss of SIRT2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance.

Fourcade S, Morató L, Parameswaran J, Ruiz M, Ruiz-Cortés T, Jové M, Naudí A, Martínez-Redondo P, Dierssen M, Ferrer I, Villarroya F, Pamplona R, Vaquero A, Portero-Otín M, Pujol A.

Aging Cell. 2017 Dec;16(6):1404-1413. doi: 10.1111/acel.12682. Epub 2017 Oct 5.

15.

Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome.

Fructuoso M, Rachdi L, Philippe E, Denis RG, Magnan C, Le Stunff H, Janel N, Dierssen M.

Free Radic Biol Med. 2018 Jan;114:122-130. doi: 10.1016/j.freeradbiomed.2017.09.021. Epub 2017 Sep 25. Review. Erratum in: Free Radic Biol Med. 2018 Mar 7;:.

PMID:
28958596
16.

Anomalous White Matter Structure and the Effect of Age in Down Syndrome Patients.

Fenoll R, Pujol J, Esteba-Castillo S, de Sola S, Ribas-Vidal N, García-Alba J, Sánchez-Benavides G, Martínez-Vilavella G, Deus J, Dierssen M, Novell-Alsina R, de la Torre R.

J Alzheimers Dis. 2017;57(1):61-70. doi: 10.3233/JAD-161112.

PMID:
28222523
17.

New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease.

Gómez-Grau M, Albaigès J, Casas J, Auladell C, Dierssen M, Vilageliu L, Grinberg D.

Sci Rep. 2017 Feb 7;7:41931. doi: 10.1038/srep41931.

18.

Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society.

Delabar JM, Allinquant B, Bianchi D, Blumenthal T, Dekker A, Edgin J, O'Bryan J, Dierssen M, Potier MC, Wiseman F, Guedj F, Créau N, Reeves R, Gardiner K, Busciglio J.

Mol Syndromol. 2016 Oct;7(5):251-261. Epub 2016 Sep 16.

19.

Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome.

Catuara-Solarz S, Espinosa-Carrasco J, Erb I, Langohr K, Gonzalez JR, Notredame C, Dierssen M.

eNeuro. 2016 Nov 8;3(5). pii: ENEURO.0103-16.2016. eCollection 2016 Sep-Oct.

20.

VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome.

Del Hoyo L, Xicota L, Langohr K, Sánchez-Benavides G, de Sola S, Cuenca-Royo A, Rodriguez J, Rodríguez-Morató J, Farré M, Dierssen M, de la Torre R; TESDAD Study Group.

Front Behav Neurosci. 2016 Oct 17;10:193. eCollection 2016.

21.

Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders.

De Toma I, Manubens-Gil L, Ossowski S, Dierssen M.

Neural Plast. 2016;2016:4235898. doi: 10.1155/2016/4235898. Epub 2016 Jul 28. Review.

22.

Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear.

D'Amico D, Gener T, de Lagrán MM, Sanchez-Vives MV, Santos M, Dierssen M.

Neuropsychopharmacology. 2017 Jan;42(2):462-472. doi: 10.1038/npp.2016.154. Epub 2016 Aug 18.

23.

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.

de la Torre R, de Sola S, Hernandez G, Farré M, Pujol J, Rodriguez J, Espadaler JM, Langohr K, Cuenca-Royo A, Principe A, Xicota L, Janel N, Catuara-Solarz S, Sanchez-Benavides G, Bléhaut H, Dueñas-Espín I, Del Hoyo L, Benejam B, Blanco-Hinojo L, Videla S, Fitó M, Delabar JM, Dierssen M; TESDAD study group.

Lancet Neurol. 2016 Jul;15(8):801-810. doi: 10.1016/S1474-4422(16)30034-5.

PMID:
27302362
24.

Overexpression of Dyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex.

Ruiz-Mejias M, Martinez de Lagran M, Mattia M, Castano-Prat P, Perez-Mendez L, Ciria-Suarez L, Gener T, Sancristobal B, García-Ojalvo J, Gruart A, Delgado-García JM, Sanchez-Vives MV, Dierssen M.

J Neurosci. 2016 Mar 30;36(13):3648-59. doi: 10.1523/JNEUROSCI.2517-15.2016.

25.

Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns.

Sanchez-Mut JV, Heyn H, Vidal E, Moran S, Sayols S, Delgado-Morales R, Schultz MD, Ansoleaga B, Garcia-Esparcia P, Pons-Espinal M, de Lagran MM, Dopazo J, Rabano A, Avila J, Dierssen M, Lott I, Ferrer I, Ecker JR, Esteller M.

Transl Psychiatry. 2016 Jan 19;6:e718. doi: 10.1038/tp.2015.214.

26.

Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome.

Catuara-Solarz S, Espinosa-Carrasco J, Erb I, Langohr K, Notredame C, Gonzalez JR, Dierssen M.

Front Behav Neurosci. 2015 Dec 11;9:330. doi: 10.3389/fnbeh.2015.00330. eCollection 2015.

27.

Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aβ42 Concentrations in Down Syndrome Young Adults.

Hoyo LD, Xicota L, Sánchez-Benavides G, Cuenca-Royo A, de Sola S, Langohr K, Fagundo AB, Farré M, Dierssen M, de la Torre R.

Front Behav Neurosci. 2015 Nov 18;9:301. doi: 10.3389/fnbeh.2015.00301. eCollection 2015.

28.

Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges.

Bofill-De Ros X, Santos M, Vila-Casadesús M, Villanueva E, Andreu N, Dierssen M, Fillat C.

BMC Genomics. 2015 Nov 6;16:907. doi: 10.1186/s12864-015-2160-6.

29.

New Perspectives for the Rescue of Cognitive Disability in Down Syndrome.

Bartesaghi R, Haydar TF, Delabar JM, Dierssen M, Martínez-Cué C, Bianchi DW.

J Neurosci. 2015 Oct 14;35(41):13843-52. doi: 10.1523/JNEUROSCI.2775-15.2015.

30.

Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease.

Xicota L, Rodriguez-Morato J, Dierssen M, de la Torre R.

Curr Drug Targets. 2017;18(2):174-195. doi: 10.2174/1389450116666150825113655. Review.

PMID:
26302801
31.

Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain.

Falsafi SK, Dierssen M, Ghafari M, Pollak A, Lubec G.

Amino Acids. 2016 Jan;48(1):103-16. doi: 10.1007/s00726-015-2062-6. Epub 2015 Aug 13.

PMID:
26269195
32.

A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials.

de Sola S, de la Torre R, Sánchez-Benavides G, Benejam B, Cuenca-Royo A, Del Hoyo L, Rodríguez J, Catuara-Solarz S, Sanchez-Gutierrez J, Dueñas-Espin I, Hernandez G, Peña-Casanova J, Langohr K, Videla S, Blehaut H, Farre M, Dierssen M; TESDAD Study Group.

Front Psychol. 2015 Jun 4;6:708. doi: 10.3389/fpsyg.2015.00708. eCollection 2015.

33.

From neural to genetic substrates of panic disorder: Insights from human and mouse studies.

Santos M, D'Amico D, Dierssen M.

Eur J Pharmacol. 2015 Jul 15;759:127-41. doi: 10.1016/j.ejphar.2015.03.039. Epub 2015 Mar 24. Review.

PMID:
25818748
34.

Opposite phenotypes of muscle strength and locomotor function in mouse models of partial trisomy and monosomy 21 for the proximal Hspa13-App region.

Brault V, Duchon A, Romestaing C, Sahun I, Pothion S, Karout M, Borel C, Dembele D, Bizot JC, Messaddeq N, Sharp AJ, Roussel D, Antonarakis SE, Dierssen M, Hérault Y.

PLoS Genet. 2015 Mar 24;11(3):e1005062. doi: 10.1371/journal.pgen.1005062. eCollection 2015 Mar.

35.

Potential role of olive oil phenolic compounds in the prevention of neurodegenerative diseases.

Rodríguez-Morató J, Xicota L, Fitó M, Farré M, Dierssen M, de la Torre R.

Molecules. 2015 Mar 13;20(3):4655-80. doi: 10.3390/molecules20034655. Review.

36.

A cluster of protein kinases and phosphatases modulated in fetal Down syndrome (trisomy 21) brain.

Weitzdoerfer R, Toran N, Subramaniyan S, Pollak A, Dierssen M, Lubec G.

Amino Acids. 2015 Jun;47(6):1127-34. doi: 10.1007/s00726-015-1941-1. Epub 2015 Mar 5.

PMID:
25740605
37.

Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome.

Pujol J, del Hoyo L, Blanco-Hinojo L, de Sola S, Macià D, Martínez-Vilavella G, Amor M, Deus J, Rodríguez J, Farré M, Dierssen M, de la Torre R.

Cortex. 2015 Mar;64:148-56. doi: 10.1016/j.cortex.2014.10.012. Epub 2014 Oct 28.

PMID:
25461715
38.

Hippocampal changes produced by overexpression of the human CHRNA5/A3/B4 gene cluster may underlie cognitive deficits rescued by nicotine in transgenic mice.

Molas S, Gener T, Güell J, Martín M, Ballesteros-Yáñez I, Sanchez-Vives MV, Dierssen M.

Acta Neuropathol Commun. 2014 Nov 11;2:147. doi: 10.1186/s40478-014-0147-1.

39.

Heterozygous deletion of the Williams-Beuren syndrome critical interval in mice recapitulates most features of the human disorder.

Segura-Puimedon M, Sahún I, Velot E, Dubus P, Borralleras C, Rodrigues AJ, Valero MC, Valverde O, Sousa N, Herault Y, Dierssen M, Pérez-Jurado LA, Campuzano V.

Hum Mol Genet. 2014 Dec 15;23(24):6481-94. doi: 10.1093/hmg/ddu368. Epub 2014 Jul 15.

PMID:
25027326
40.

RhoE deficiency alters postnatal subventricular zone development and the number of calbindin-expressing neurons in the olfactory bulb of mouse.

Ballester-Lurbe B, González-Granero S, Mocholí E, Poch E, García-Manzanares M, Dierssen M, Pérez-Roger I, García-Verdugo JM, Guasch RM, Terrado J.

Brain Struct Funct. 2015 Nov;220(6):3113-30. doi: 10.1007/s00429-014-0846-1. Epub 2014 Jul 10.

PMID:
25009316
41.

The role of nicotinic receptors in shaping and functioning of the glutamatergic system: a window into cognitive pathology.

Molas S, Dierssen M.

Neurosci Biobehav Rev. 2014 Oct;46 Pt 2:315-25. doi: 10.1016/j.neubiorev.2014.05.012. Epub 2014 May 29. Review.

PMID:
24879992
42.

Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage.

Souchet B, Guedj F, Sahún I, Duchon A, Daubigney F, Badel A, Yanagawa Y, Barallobre MJ, Dierssen M, Yu E, Herault Y, Arbones M, Janel N, Créau N, Delabar JM.

Neurobiol Dis. 2014 Sep;69:65-75. doi: 10.1016/j.nbd.2014.04.016. Epub 2014 May 4.

PMID:
24801365
43.

Cognition and hippocampal plasticity in the mouse is altered by monosomy of a genomic region implicated in Down syndrome.

Sahún I, Marechal D, Pereira PL, Nalesso V, Gruart A, Garcia JM, Antonarakis SE, Dierssen M, Herault Y.

Genetics. 2014 Jul;197(3):899-912. doi: 10.1534/genetics.114.165241. Epub 2014 Apr 21.

44.

The α3β4* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies.

Muldoon PP, Jackson KJ, Perez E, Harenza JL, Molas S, Rais B, Anwar H, Zaveri NT, Maldonado R, Maskos U, McIntosh JM, Dierssen M, Miles MF, Chen X, De Biasi M, Damaj MI.

Br J Pharmacol. 2014 Aug;171(16):3845-57. doi: 10.1111/bph.12741.

45.

DREAM controls the on/off switch of specific activity-dependent transcription pathways.

Mellström B, Sahún I, Ruiz-Nuño A, Murtra P, Gomez-Villafuertes R, Savignac M, Oliveros JC, Gonzalez P, Kastanauskaite A, Knafo S, Zhuo M, Higuera-Matas A, Errington ML, Maldonado R, DeFelipe J, Jefferys JG, Bliss TV, Dierssen M, Naranjo JR.

Mol Cell Biol. 2014 Mar;34(5):877-87. doi: 10.1128/MCB.00360-13. Epub 2013 Dec 23.

46.

Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: implications for Down syndrome.

Mouton-Liger F, Sahún I, Collin T, Lopes Pereira P, Masini D, Thomas S, Paly E, Luilier S, Même S, Jouhault Q, Bennaï S, Beloeil JC, Bizot JC, Hérault Y, Dierssen M, Créau N.

Neurobiol Dis. 2014 Mar;63:92-106. doi: 10.1016/j.nbd.2013.11.016. Epub 2013 Nov 28.

PMID:
24291518
47.

Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes.

Del Pino I, García-Frigola C, Dehorter N, Brotons-Mas JR, Alvarez-Salvado E, Martínez de Lagrán M, Ciceri G, Gabaldón MV, Moratal D, Dierssen M, Canals S, Marín O, Rico B.

Neuron. 2013 Sep 18;79(6):1152-68. doi: 10.1016/j.neuron.2013.07.010.

48.

Hippocampal hyperexcitability underlies enhanced fear memories in TgNTRK3, a panic disorder mouse model.

Santos M, D'Amico D, Spadoni O, Amador-Arjona A, Stork O, Dierssen M.

J Neurosci. 2013 Sep 18;33(38):15259-71. doi: 10.1523/JNEUROSCI.2161-13.2013.

49.

Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.

De la Torre R, De Sola S, Pons M, Duchon A, de Lagran MM, Farré M, Fitó M, Benejam B, Langohr K, Rodriguez J, Pujadas M, Bizot JC, Cuenca A, Janel N, Catuara S, Covas MI, Blehaut H, Herault Y, Delabar JM, Dierssen M.

Mol Nutr Food Res. 2014 Feb;58(2):278-88. doi: 10.1002/mnfr.201300325. Epub 2013 Sep 14.

PMID:
24039182
50.

DNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease.

Sanchez-Mut JV, Aso E, Panayotis N, Lott I, Dierssen M, Rabano A, Urdinguio RG, Fernandez AF, Astudillo A, Martin-Subero JI, Balint B, Fraga MF, Gomez A, Gurnot C, Roux JC, Avila J, Hensch TK, Ferrer I, Esteller M.

Brain. 2013 Oct;136(Pt 10):3018-27. doi: 10.1093/brain/awt237. Epub 2013 Sep 11.

Supplemental Content

Loading ...
Support Center